Company pays over $81m for allegedly promoting topiramate for unapproved usesBMJ 2010; 340 doi: https://doi.org/10.1136/bmj.c2848 (Published 27 May 2010) Cite this as: BMJ 2010;340:c2848
- Zosia Kmietowicz
Two subsidiaries of drug giant Johnson & Johnson have agreed to pay fines of more than $81m (£56m; €65m) for allegedly illegal promotion of the epilepsy drug topiramate (Topamax) for psychiatric uses, the US Justice Department announced on 24 May.
Ortho-McNeil Pharmaceutical LLC, one of the subsidiaries, pleaded guilty to one count of misdemeanour for promoting topiramate for uses that were not approved by the US Food and Drug Administration (FDA) and was ordered to pay a criminal fine of $6.14m.
The government says that the company promoted topiramate for unapproved uses …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial